Randomized, Double-Blind, Parallel-Group Active-Controlled Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients.
Latest Information Update: 07 May 2024
At a glance
- Drugs Amisulpride (Primary)
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
Most Recent Events
- 07 May 2024 New trial record
- 30 Apr 2024 According to Eagle Pharmaceuticals media release,Preliminary results from this study expected in the first half of 2025
- 30 Apr 2024 According to Eagle Pharmaceuticals media release,Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting in pediatric patients at the upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting, which is being held May 2-4, 2024, in Savannah, Georgia.